Evidence map›Paper›PMID 29949432›Full record

Trial reportEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2018

THE EFFICACY AND SAFETY OF CO-ADMINISTRATION OF SITAGLIPTIN WITH METFORMIN IN PATIENTS WITH TYPE 2 DIABETES AT HOSPITAL DISCHARGE.

Roma Y Gianchandani, Francisco J Pasquel, Daniel J Rubin, Kathleen M Dungan, Priyathama Vellanki, Heqiong Wang, Isabel Anzola, Patricia Gomez, Israel Hodish, Sangeeta Lathkar-Pradhan and 2 more

Open access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Management of diabetes and hyperglycaemia in the hospital.The lancet. Diabetes & endocrinology · 2021 · on this map
    Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Roma Y Gianchandani
Francisco J Pasquel
Daniel J Rubin
Kathleen M Dungan
Priyathama Vellanki
Heqiong Wang
Isabel Anzola
Patricia Gomez
Israel Hodish
Sangeeta Lathkar-Pradhan
Jennifer Iyengar
Guillermo E Umpierrez
Emory University · USUniversity of Michigan–Ann Arbor · USOhio University · USPhiladelphia University · US

Funding

Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Translational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4M
Predicting and Preventing Hospital Readmission in Patients with Diabetes and CVDK23DK102963 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI RUBIN, DANIEL J · 2015 to 2018
$713k
NCATS NIH HHS UL1 TR000454NIDDK NIH HHS K23 DK102963NIDDK NIH HHS P30 DK111024
6 · The paper itself

Abstract

objectiveFew randomized controlled trials have focused on the optimal management of patients with type 2 diabetes (T2D) during the transition from the inpatient to outpatient setting. This multicenter open-label study explored a discharge strategy based on admission hemoglobin A1c (HbA1c) to guide therapy in general medicine and surgery patients with T2D.

methodsPatients with HbA1c ≤7% (53 mmol/mol) were discharged on sitagliptin and metformin; patients with HbA1c between 7 and 9% (53-75 mmol/mol) and those >9% (75 mmol/mol) were discharged on sitagliptinmetformin with glargine U-100 at 50% or 80% of the hospital daily dose. The primary outcome was change in HbA1c at 3 and 6 months after discharge.

resultsMean HbA1c on admission for the entire cohort (N = 253) was 8.70 ± 2.3% and decreased to 7.30 ± 1.5% and 7.30 ± 1.7% at 3 and 6 months ( P<.001). Patients with HbA1c <7% went from 6.3 ± 0.5% to 6.3 ± 0.80% and 6.2 ± 1.0% at 3 and 6 months. Patients with HbA1c between 7 and 9% had a reduction from 8.0 ± 0.6% to 7.3 ± 1.1% and 7.3 ± 1.3%, and those with HbA1c >9% from 11.3 ± 1.7% to 8.0 ± 1.8% and 8.0 ± 2.0% at 3 and 6 months after discharge (both P<.001). Clinically significant hypoglycemia (<54 mg/dL) was observed in 4%, 4%, and 7% among patients with a HbA1c <7%, 7 to 9%, and >9%, while a glucose <40 mg/dL was reported in <1% in all groups.

conclusionThe proposed HbA1c-based hospital discharge algorithm using a combination of sitagliptin-metformin was safe and significantly improved glycemic control after hospital discharge in general medicine and surgery patients with T2D. ABBREVIATIONS: BG = blood glucose; DPP-4 = dipeptidyl peptidase-4; eGFR = estimated glomerular filtration rate; HbA1c = hemoglobin A1c; T2D = type 2 diabetes.

Indexed as

AdultAgedBlood GlucoseDiabetes Mellitus, Type 2Drug Therapy, CombinationFemaleGlycated HemoglobinHumansMaleMetforminMiddle AgedPatient DischargeProspective StudiesSitagliptin PhosphateBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanMetforminSitagliptin Phosphate

Identifiers

PMID29949432
PMCPMC6657798
OpenAlexW2810167452

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.